TrialThe Journal of clinical endocrinology and metabolism2022

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.

Agnès Linglart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.